Page 3 - Kymab News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kymab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kymab Today - Breaking & Trending Today
By Denny Jacob Y-mAbs Therapeutics named Michael Rossi president and chief executive officer. The commercial-stage biopharmaceutical company said Rossi, who. ....
By Denny Jacob Y-mAbs Therapeutics' investigational new drug application for CD38-SADA was cleared by the Food and Drug Administration. The commercial-stage. ....
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has received a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. […] ....
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) was the target of a large growth in short interest in August. As of August 15th, there was short interest totalling 3,140,000 shares, a growth of 52.4% from the July 31st total of 2,060,000 shares. Based on an average daily volume of 244,800 shares, the days-to-cover ratio […] ....
Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) had its target price cut by Morgan Stanley from $7.00 to $5.00 in a report published on Monday morning, MarketBeat Ratings reports. They currently have an underweight rating on the stock. Several other research analysts also recently commented on the company. Bank of America lifted their target price on […] ....